These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6219847)

  • 1. Interactions between mezlocillin and sisomicin in vitro and in patients with normal and various degrees of impaired renal function.
    Kampf D; Schurig R; Bergs A; Förster D
    Clin Nephrol; 1983 Jan; 19(1):37-44. PubMed ID: 6219847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies with azlocillin, mezlocillin, penicillin-g-potassium and sisomicin on tolerance in the cornea and the kinetics of inhibiting concentrations in the cornea and aqueous humor in rabbits].
    Gauri KK; Finck J; Claussen B; Schassan HH; Fedder J; Weuta H
    Infection; 1982; 10 Suppl 3():S221-6. PubMed ID: 6218119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic action between sisomicin and mezlocillin against gram-negative bacteria and Staphylococcus aureus.
    Soares LA; Trabulsi LR
    Arzneimittelforschung; 1979; 29(12a):1934-7. PubMed ID: 543894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic studies of azlocillin, mezlocillin, cephalothin and sisomicin in rabbits.
    Dzierzanowska D; Patzer J; Jeljaszewicz J
    Infection; 1982; 10 Suppl 3():S217-20. PubMed ID: 6218118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sisomicin: in vitro activity and pharmacokinetics.
    Simon C; Maleryzk V; Ahlendorf W
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):145-9. PubMed ID: 649233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
    Dzierzanowska D; Jeljaszewicz J
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Sep; 255(2-3):346-55. PubMed ID: 6417945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin.
    Henderson JL; Polk RE; Kline BJ
    Am J Hosp Pharm; 1981 Aug; 38(8):1167-70. PubMed ID: 6455916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of severe febrile neutropenia (author's transl)].
    Meuret G; Roux A; Heim ME; Westerhausen M
    Dtsch Med Wochenschr; 1980 Dec; 105(51):1776-9. PubMed ID: 6449360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo inactivation of gentamicin by carbenicillin and ticarcillin.
    Kradjan WA; Burger R
    Arch Intern Med; 1980 Dec; 140(12):1668-70. PubMed ID: 7458498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mezlocillin during haemodialysis.
    Thorsteinsson SB; Steingrimsson O; Asmundsson P; Bergan T
    Scand J Infect Dis Suppl; 1981; 29():59-63. PubMed ID: 6458883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sisomicin. The mechanism of admixture inactivation and formation].
    Kartseva VD; Libinson GS; Portnoĭ IuA; Kruzhkova NG
    Antibiotiki; 1981 Nov; 26(11):825-8. PubMed ID: 7325615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative review of two new wide-spectrum penicillins: mezlocillin and piperacillin.
    Russo J; Russo ME
    Clin Pharm; 1982; 1(3):207-16. PubMed ID: 6224627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of lividomycin, aminkacin and sisomicin in patients with chronic renal insufficiency].
    Leroy A; Oksenhendler G; Fillastre JP; Humbert G
    J Urol Nephrol (Paris); 1977 Sep; 83(9):738-41. PubMed ID: 243544
    [No Abstract]   [Full Text] [Related]  

  • 16. Gentamicin and ticarcillin in subjects with end-stage renal disease. Comparison of two assay methods and evaluation of inactivation rate.
    Russo ME; Atkin-Thor E
    Clin Nephrol; 1981 Apr; 15(4):175-80. PubMed ID: 7237864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined action of decreasing concentrations of azlocillin and sisomicin on Pseudomonas aeruginosa as assessed in a dynamic in vitro model.
    Haller I
    Infection; 1982; 10 Suppl 3():S229-33. PubMed ID: 6818155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia.
    Hanson B; Coppens L; Klastersky J
    J Antimicrob Chemother; 1982 Oct; 10(4):335-41. PubMed ID: 6216236
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.